Lori M Minasian

Multilevel modeling and value of information in clinical trial decision support

Bruce Tidor, Brendan Murphy, Paul M Coates, 2014, BMC Systems Biology.

Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Bryan J Weiner, Lori M Minasian, L. Minasian, 2012, Journal of oncology practice.

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.

Joseph Lipscomb, Lori M Minasian, Jeffrey S Abrams, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

Dawn L Hershman, Lori M Minasian, L. Minasian, 2019, Journal of the National Cancer Institute.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Ian M Thompson, Lori M Minasian, Scott M Lippman, 2014, Journal of the National Cancer Institute.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Amy P Abernethy, Ram Chilukuri, Tito R Mendoza, 2014, Journal of the National Cancer Institute.

Long-term survival of participants in the prostate cancer prevention trial.

Ian M Thompson, Lori M Minasian, I. Thompson, 2013, The New England journal of medicine.

Prevention and early detection of prostate cancer.

Timothy J Wilt, Dragan Ilic, Jack Cuzick, 2014, The Lancet. Oncology.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Amy P Abernethy, Tito R Mendoza, Charles S Cleeland, 2015, JAMA oncology.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Michael M Lieber, J Michael Gaziano, Ian M Thompson, 2005, Journal of the National Cancer Institute.